Subsequent Treatments
7.1.1	This is a repeating form. If the patient had multiple subsequent treatments beyond the previous six, please complete this and if needed, add a new repeating form or instance by either clicking the dropdown arrow next to “Current instance:” above and select “+Add new” OR at the bottom, press the blue drop down arrow and select “Save & Add New Instance”.	Descriptive
Subsequent Treatment
7.2.1	Subsequent treatment	Checkbox 1, rx_sub___1 Conventional transarterial chemoembolization (cTACE)|2, rx_sub___2 Drug-eluting bead (DEB)-TACE|3, rx_sub___3 Radiofrequency ablation (RFA)|4, rx_sub___4 Irreversible electroporation|5, rx_sub___5 Percutaneous ethanol injection (PEI)|6, rx_sub___6 Hepatic resection|7, rx_sub___7 Microwave ablation|8, rx_sub___8 Medication|9, rx_sub___9 Stereotactic body ablation radiotherapy|10, rx_sub___10 Liver transplant|11, rx_sub___11 Selective internal radiation therapy (SIRT)|12, rx_sub___12 No treatment|13, rx_sub___13 Other {rx_sub_other}|14, rx_sub___14 Distant hepatic recurrence|15, rx_sub___15 None of the above
7.2.2	Other	Text
7.2.3	Medications	Checkbox 1, rx_submed___1 Sorafenib|2, rx_ submed ___2 Lenvima (Lenvatinib)|3, rx_ submed ___3 Atezolizumab|4, rx_ submed ___4 Others: please specify: {rx_ submed _other}|5, rx_ submed ___5 Clinical trial medication: please specify: {rx_ submed _clintrial}
7.2.4	Other medications	Text
7.2.5	Clinical trial medications	Text
7.2.6	Date of subsequent treatment	Date
7.2.7	Reason no treatment	Checkbox 1, rx_sub_notreat___1 Patient unable to tolerate treatment|2, rx_sub_notreat___2 Patient moved before treatment|3, rx_sub_notreat___3 Patient lost to follow up|4, rx_sub_notreat___4 Patient died before treatment
7.2.8	Treatment response at time interval of subsequent treatment	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
7.2.9	Date of response assessment to subsequent treatment	Date
7.2.10	Date complete response confirmed after subsequent treatment	Date
7.2.11	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
7.2.12	Date of recurrence	Date
7.2.13	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
7.2.14	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
7.2.15	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
7.2.16	Where is the extrahepatic spread?	Text
7.2.17	Complications after subsequent treatment	Checkbox 1, rx_sub_complications___1 Liver-related morbidity|2, rx_sub_complications___2 Post-procedural infections|3, rx_sub_complications___3 Post-procedural bleeding|4, rx_sub_complications___4 Bile duct injury|5, rx_sub_complications___5 Respiratory events|6, rx_sub_complications___6 Local events|7, rx_sub_complications___7 Other {compsub_other}|8, rx_sub_complications___8 Systemic treatment (chemotherapy)
7.2.18	Other complications	Text
Form Status
7.3.1	Complete?	Dropdown 0, Incomplete|1, Unverified|2, Complete